IL1B and neoplasm: In light of the behavioural effect of 5-ASA/SP treatment on the SPT despite failure to prevent tumour-associated increases in IL-1β and IL-6, an investigation of a wider array of inflammatory markers might help clarify the observed behavioural effects of these drugs in our model.